top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

25.37 +0.02 (+0.08%)
Delayed Quote Updated: 1:48 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
3 Stocks Under $50 We Think Twice About
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
Topics Supply Chain
News headline image
3 Reasons to Avoid AMPH and 1 Stock to Buy Instead
Over the past six months, Amphastar Pharmaceuticals has been a great trade, beating the S&P 500 by 11.4%. Its stock price has climbed to $24.97, representing... 
Via StockStory
Topics Stocks Supply Chain
News headline image
3 Russell 2000 Stocks We Find Risky
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
3 Small-Cap Stocks with Warning Signs
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stands Out as a Quality Investing Candidate ↗
Via Chartmill
Amphastar Pharmaceuticals (NASDAQ:AMPH) Beats Q2 Earnings Estimates, Shares Rise After Hours ↗
Via Chartmill
Amphastar Pharmaceuticals (NASDAQ:AMPH) Screens as a High-Quality Stock with Deep Value Appeal ↗
Via Chartmill
News headline image
Amphastar Pharmaceuticals (NASDAQ:AMPH): Strongest Q2 Results from the Generic Pharmaceuticals Group
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q2 generic pharmaceuticals e... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
News headline image
1 Cash-Producing Stock on Our Buy List and 2 We Question
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
Amphastar (AMPH) Q2 2026 Earnings Call Transcript ↗
New product launches drove 5% revenue growth and margin expansion. 
Via The Motley Fool
Topics Earnings
News headline image
The Top 5 Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call
Amphastar Pharmaceuticals delivered results in Q2 that surpassed Wall Street expectations, reflecting continued strength across its diversified product portf... 
Via StockStory
Topics Earnings
News headline image
AMPH Q2 Deep Dive: Portfolio Expansion and Pipeline Progress Drive Results
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 5.4% year on y... 
Via StockStory
News headline image
Amphastar Pharmaceuticals Q2 Earnings Call Highlights ↗
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is... 
Via MarketBeat
Topics Earnings
News headline image
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 5.4% year o... 
Via StockStory
News headline image
What To Expect From Amphastar Pharmaceuticals’s (AMPH) Q2 Earnings
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting results this Thursday after market hours. Here’s what to look for. Amphastar ... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Value Stock to Own for Decades and 2 Facing Challenges
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
3 Reasons AMPH is Risky and 1 Stock to Buy Instead
Amphastar Pharmaceuticals has gotten torched over the last six months - since January 2026, its stock price has dropped 27.6% to $18.92 per share. This was p... 
Via StockStory
Topics Supply Chain
News headline image
3 Stocks Under $50 We Keep Off Our Radar
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
Topics Energy
News headline image
1 of Wall Street’s Favorite Stocks to Research Further and 2 Facing Challenges
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
1 Healthcare Stock to Consider Right Now and 2 We Brush Off
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
Topics Artificial Intelligence
News headline image
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth ↗
Amphastar Pharmaceuticals (NASDAQ:AMPH) is positioning itself for a broader shift from complex generics toward proprietary medicines and biosimilars, Chief Financial Officer and Executive Vice... 
Via MarketBeat
News headline image
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag ↗
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in... 
Via MarketBeat
News headline image
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
Via ACCESS Newswire
News headline image
3 Stocks Under $50 with Open Questions
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
News headline image
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today
What Happened? Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 2.8% in the morning session after Wells Fargo downgraded the comp... 
Via StockStory
News headline image
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook ↗
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to... 
Via MarketBeat
News headline image
The 5 Most Interesting Analyst Questions From Amphastar Pharmaceuticals’s Q1 Earnings Call
Amphastar Pharmaceuticals’ first quarter was marked by flat revenue and a significant shortfall in non-GAAP profit compared to analyst expectations, promptin... 
Via StockStory
Topics Earnings
News headline image
Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page